Skip to main content
. 2023 Jan 24;29(9):1719–1729. doi: 10.1158/1078-0432.CCR-22-2177

Figure 4.

Figure 4. High bTMB at baseline is associated with dominant APOBEC mutational signatures and upregulation of specific oncogenic signaling pathways. A, Dominant APOBEC mutational signatures (SBS2 and SBS13) were enriched in patients with high (N = 13) versus low (N = 37) bTMB scores (defined by upper quartile cutoff). Dominant SBS5 (unknown) and SBS6 (defective DNA mismatch repair signatures) were observed across patients with high and low bTMB scores. B, The proportion of dominant APOBEC signatures was significantly greater in patients with high bTMB scores versus low bTMB scores (Fisher exact test). C, The median bTMB score was significantly higher in patients with dominant APOBEC signatures versus other signatures (Wilcoxon rank sum test).

High bTMB at baseline is associated with dominant APOBEC mutational signatures and upregulation of specific oncogenic signaling pathways. A, Dominant APOBEC mutational signatures (SBS2 and SBS13) were enriched in patients with high (N = 13) versus low (N = 37) bTMB scores (defined by upper quartile cutoff). Dominant SBS5 (unknown) and SBS6 (defective DNA mismatch repair signatures) were observed across patients with high and low bTMB scores. B, The proportion of dominant APOBEC signatures was significantly greater in patients with high bTMB scores versus low bTMB scores (Fisher exact test). C, The median bTMB score was significantly higher in patients with dominant APOBEC signatures versus other signatures (Wilcoxon rank sum test).